Home>>Signaling Pathways>> Neuroscience>> Dopamine Receptor>>(−)-Apomorphine (hydrochloride)
(−)-Apomorphine (hydrochloride) Catalog No.GC10003

Prototypical dopamine agonist

Size Price Stock Qty
10mM (in 1mL DMSO)
$42.00
In stock
50mg
$92.40
In stock
100mg
$168.00
In stock

Customer Review

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:

Chemical Properties

Cas No. 314-19-2 SDF
Synonyms NSC 11442, Uprima
Chemical Name (R)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol hydrochloride
Canonical SMILES OC1=C2C3=C4[C@@H](CC2=CC=C1O)N(C)CCC4=CC=C3.Cl
Formula C17H17NO2.HCl M.Wt 303.79
Solubility 1mg/mL in ethanol, 15mg/mL in DMSO, 20mg/mL in DMF Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

Background

(−)-Apomorphine is a non-selective dopamine receptor agonist that exhibits pKi values of 6.43, 7.08, 7.59, 8.36, and 7.83 for human recombinant D1, D2L, D3, D4, and D5 receptors, respectively.[1],[2] It produces biphasic effects on locomotor activity and displays anti-parkinsonian and neuroprotective actions.[1,][3],[4]

Reference:

[1]. Millan, M.J., Maiofiss, L., Cussac, D., et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes J. Pharmacol. Exp. Ther. 303(2), 791-804 (2002).
[2]. Seeman, P., Grigoriadis, D.E., and Niznik, H.B. Selectivity of agonists and antagonists at D2 dopamine receptos compared to D1 and S2 receptors Drug Development Research 9, 63-69 (1986).
[3]. Newman-Tancredi, A., Cussac, D., Audinot, V., et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and α1/α2-adrenoceptor Journal of Pharmacology and Experimental Therapeutics 303(2), 805-814 (2002).
[4]. Schechter, M.D., Rosecrans, J.A., and Glennon, R.A. Comparison of behavioral effects of cathinone, amphetamine and apomorphine Pharmacology, Biochemistry, and Behavior 20(2), 181-184 (1984).